Regeneron officer proposes $3.79M share sale

The notice links the proposed shares to three dated option grants and names UBS Financial Services Inc. in the broker information.

Available on EDGAR 11/04/2026 - 04:03 PM EST Accepted by SEC EDGAR 11/04/2026 - 04:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. officer Jason Pitofsky filed a notice covering a proposed sale of 3,883 common shares, with an indicated aggregate market value of $3,789,808. UBS Financial Services Inc. is named in the broker information, and the approximate sale date is November 4, 2026. The notice lists cashless exercises tied to stock option grants dated December 9, 2020, December 8, 2021, and December 16, 2022.

Key Figures

Shares proposed for sale: 3,883 common shares Aggregate market value: $3,789,808 Shares outstanding: 101,630,713 shares +3 more

6 metrics

Shares proposed for sale 3,883 common shares Proposed sale

Aggregate market value $3,789,808 Proposed sale

Shares outstanding 101,630,713 shares Issuer shares outstanding

Shares associated with December 9, 2020 option grant 905 shares Cashless exercise

Shares associated with December 8, 2021 option grant 1,478 shares Cashless exercise

Shares associated with December 16, 2022 option grant 1,500 shares Cashless exercise

Key Terms

Rule 144, cashless exercise, stock option grant

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

cashless exercise financial

"cashless exercise common"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

stock option grant financial

"stock option grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares does Jason Pitofsky's notice cover?

The notice covers 3,883 common shares with an indicated aggregate market value of $3,789,808. UBS Financial Services Inc. is named in the broker information, and the approximate sale date is November 4, 2026.

Which option grants are associated with Jason Pitofsky's REGN sale notice?

The notice lists 905 shares from a December 9, 2020 stock option grant, 1,478 shares from a December 8, 2021 grant, and 1,500 shares from a December 16, 2022 grant; each is identified with a cashless exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002009236
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Regeneron Pharmaceuticals Inc
SEC File Number	000-19034
Address of Issuer	777 Old Saw Mill Road Tarrytown NEW YORK 10591
Phone	9148477000
Name of Person for Whose Account the Securities are To Be Sold	Jason Pitofsky
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	3883	3789808	101630713	11/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/09/2020	stock option grant	Regeneron Pharmaceutical Inc			905	11/04/2026	cashless exercise
common	12/08/2021	stock option grant	Regeneron Pharmaceutical Inc			1478	11/04/2026	cashless exercise
common	12/16/2022	stock option grant	Regeneron Pharmaceutical Inc			1500	11/04/2026	cashless exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/JOSEPH CASSIDY, for UBS Financial Services Inc, as attorney-in-fact for Jason Pitofsky
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)